持续性非卧床腹膜透析患者的甲状旁腺功能亢进：脉冲式口服骨化三醇治疗
Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
作者信息
Juergensen P H, Finkelstein F O, Cooper K, Santacroce S, Kliger A S
机构信息
Department of Internal Medicine, Yale University, Hospital of St. Raphael.
出版信息
Adv Perit Dial. 1993;9:257-9.
PMID:8105938
Abstract
Hyperparathyroidism remains a cause of significant morbidity in dialysis patients. We studied pulse oral calcitriol, 5.0 micrograms biweekly to control hyperparathyroidism in 12 continuous ambulatory peritoneal dialysis (CAPD) patients. Parathyroid hormone (PTH) levels fell, while calcium and phosphorus levels remained in good control. Pulse oral calcitriol is an effective therapy for hyperparathyroidism in CAPD patients.
摘要
甲状旁腺功能亢进仍然是透析患者发病的一个重要原因。我们对12名持续性非卧床腹膜透析（CAPD）患者进行了研究，每两周口服5.0微克脉冲式骨化三醇以控制甲状旁腺功能亢进。甲状旁腺激素（PTH）水平下降，而钙和磷水平仍得到良好控制。脉冲式口服骨化三醇是治疗CAPD患者甲状旁腺功能亢进的有效疗法。
Zotero 插件